Form 8-K - Current report:
SEC Accession No. 0001493152-22-030695
Filing Date
2022-11-04
Accepted
2022-11-04 16:43:04
Documents
19
Period of Report
2022-11-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39711
2 form8-k_001.jpg GRAPHIC 7428
3 ex99-1.htm EX-99.1 1109
4 ex99-2.htm EX-99.2 1247
5 ex99-3.htm EX-99.3 1026
6 ex99-1_001.jpg GRAPHIC 101756
7 ex99-2_001.jpg GRAPHIC 100312
8 ex99-3_001.jpg GRAPHIC 109278
  Complete submission text file 0001493152-22-030695.txt   666613

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE lpcn-20221104.xsd EX-101.SCH 3227
10 XBRL LABEL FILE lpcn-20221104_lab.xml EX-101.LAB 34240
11 XBRL PRESENTATION FILE lpcn-20221104_pre.xml EX-101.PRE 22359
13 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3605
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 221362858
SIC: 2834 Pharmaceutical Preparations